CoChat

n‐3 fatty acids decrease colonic epithelial cell proliferation in high‐risk bowel mucosa

Huang, Yun‐Ching, Jessup, J. Milburn, Forse, R. Armour, Flickner, Stacy, Pleskow, Douglas, Anastopoulos, Harry T., Van Ritter, Blackburn, George L. · 1996 · Lipids
Cited by 63

The DOI matches its Crossref record.

Abstract

The n‐3 fatty acids (C20∶5, eicosapentaenoic acid; C22∶6, docosahexaenoic, acid) may be important in the development, growth, and metastasis of colon cancer, a leading cause of death in North America. Patients who have had a bowel neoplasm have a high risk of developing a second neoplasm, and this risk is associated with a high percentage of cells correspond to the S phase of bromodeoxyuridine (BrdUrd) labeling in mucosal epithelial cells. To determine the effect of n‐3 fatty acid supplementation on DNA synthesis of rectal mucosa, patients with stage 1 or stage 2 colon carcinoma or adenomatous polyps were randomized to consume either 9 g/d n‐3 fatty acid capsules or 9 g/d placebo capsules. Plasma phospholipid fatty acid analysis and proctoscopic mucosal biopsies were performed at baseline, 3, and 6 mon. Colonic crypts were isolated from the mucosa, disassociated with enzymes, and incubated with BrdUrd, and %S phase was measured by flow cytometry. The plasma phospholipid n‐6/n‐3 ratio was determined by gas chromatography. Supplement compliance was assessed by plasma phospholipid n‐6/n‐3 ratio. Mean capsule consumption in these two group was 82%. Prior to supplementation, there were no significant differences in the %S phase and the plasma n‐6/n‐3 ratio between these groups. Patients whose colonic epithelial cells indicated hyperproliferation at baseline showed a strongly positive correlation to the %S phase of BrdUrd uptake and the n‐6/n‐3 ratio. There was no significant change after n‐3 treatment in patients with low baseline. Those in the placebo group showed no significant difference in n‐6/n‐3 ratio, although there was an increase in the %S phase of BrdUrd uptake at 6 mon. The n‐3 group did not have significant side effects, and polyps were not found after completing 12 mon of n‐3 fatty acid supplementation. This study suggests that n‐3 fatty acid may be a useful chemopreventive agent in some patients as reflected in a plasma biomarker of colon tumor growth and metastasis. A low plasma phospholipid n‐6/n‐3 fatty acid ratio may serve as a nutritional marker that is associated with colonic epithelial cell hyperproliferation in the n‐3‐supplemented group as compared with the placebo group. Characteristics of mucosal proliferation at baseline may be a crucial factor for the effect of n‐3 fatty acid supplementation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/bf02637099

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Huang, Y., Jessup, J. M., Forse, R. A., Flickner, S., Pleskow, D., Anastopoulos, H. T., Ritter, V., & Blackburn, G. L.
Venue
Lipids
Publisher
Wiley
Published
1996-01
Volume
31
Issue
1Part2
Pages
S313-7
ISSN
  • 0024-4201 (ISSN-L)
  • 1558-9307
OpenAlex
W2065918867
Cited by
63
References
0
FWCI
3.31
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.